ANN ARBOR, Mich., Nov. 13 /PRNewswire/ -- NanoBio Corporation announced today that it will present new data in four presentations that detail milestones in its clinical and preclinical development programs in onychomycosis, acne, herpes labialis and genital herpes during the American Association of Pharmaceutical Scientists (AAPS) meeting November 16-20, 2008 in Atlanta, GA.
These studies confirm the skin permeation, overall safety and long-term stability of nanoemulsion-based therapies. The data support the continued development of NanoBio treatments for a wide range of skin and mucosal infections, including NanoBio’s lead products identified above as well as treatments for tinea capitis (ringworm), molluscum contagiosum (pox virus warts) and other topical fungal, bacterial and viral infections.
About NanoBio
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, and a broad platform of mucosal vaccines. NanoBio has demonstrated robust efficacy and safety in randomized, double-blind, placebo-controlled phase 2a and phase 2b studies involving over 800 subjects with recurrent herpes labialis. A large phase 2 trial is nearing completion in onychomycosis and clinical trials are planned for acne and an influenza mucosal vaccine in 2009. The company’s headquarters and laboratory facilities are located in Ann Arbor, Mich.
CONTACT: John Coffey, Vice President, Business Development, of NanoBio
Corporation, +1-734-302-9107, john.coffey@nanobio.com
Web site: http://www.NanoBio.com/
